Substance
NIVOLUMAB
Global reference: every product and company linked to this substance.
- cas: 946414-94-4
- ncit: C68814
- rxnorm: 1597876
- unii: 31YO63LBSN
BMS-936558 · BMS-986298 · MDX-1106 · MDX1106 · nivolumab [INN] · NIVOLUMAB [JAN] · NIVOLUMAB [USAN] · Nivolumab [WHO-DD] · ONO-4538 · OPDIVO · OPDIVO QVANTIG COMPONENT NIVOLUMAB · OPDUALAG COMPONENT NIVOLUMAB
Revenue by product (3)
| Company | Product | Latest period | Revenue |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY COMMON STOCK | OPDIVO | Q2 2026 | $2.7B |
| BRISTOL-MYERS SQUIBB COMPANY COMMON STOCK | OPDIVO | Q2 2026 | $2.7B |
| BRISTOL-MYERS SQUIBB COMPANY COMMON STOCK | OPDUALAG | Q2 2026 | $349.0M |
A figure belongs to the product it was reported for. It is never summed across companies or across a company's products, so one substance in three products shows three figures.
Products containing this substance (4)
- OPDIVO · BRISTOL-MYERS SQUIBB COMPANY COMMON STOCK
- OPDIVO QVANTIG · BRISTOL-MYERS SQUIBB COMPANY COMMON STOCK
- OPDUALAG · BRISTOL-MYERS SQUIBB COMPANY COMMON STOCK
- OPDIVO · BRISTOL-MYERS SQUIBB COMPANY COMMON STOCK